Dallas, Texas, March 22, 2022 (GLOBE NEWSWIRE) -- North American Cannabis Holdings, Inc. (OTC Pink: USMJ) today announced the company has secured a financing commitment to construct a state-of-the-art indoor marijuana grow operation.
USMJ has recently confirmed its eligibility to apply for the new adult-use marijuana cultivation license recently passed into law in the State of New York.
In February, New York passed a new law to provide provisional marijuana cultivation licenses to existing hemp businesses.
USMJ has a subsidiary that has been growing hemp for CBD for the past four years. The subsidiary has received an invitation from the New York Office of Cannabis Management (OCM) to apply for the provisional adult-use cannabis license.
In preparation for the license, USMJ has developed plans and secured a financing commitment to build a state of the art indoor grow operation.
USMJ is founded on the core belief that cannabis makes people's lives better. Cannabis can fight disease, improve wellness and do so in an environmentally sustainable manner. North American Cannabis Holdings is dedicated to finding the best possible applications for cannabis to serve consumers. The Company operates USMJ.com and is dedicated to Ongoing Cannabis Consumer Product Development that it can incubate into Future Spin-offs.
USMJ has one spin-off and dividend issuance so far in its cannabis incubation operational history having issued shares of Puration, Inc. (OTC Pink: PURA) in the past. USMJ continues to work closely with PURA and recently acquired a CBD sports nutrition beverage product from PURA in a royalty agreement. The EVERx CBD Sports Nutrition Beverage acquired by USMJ is bottled by Alkame Holdings, Inc. (OTC Pink: ALKM).
Visit the company’s ecommerce site now and bookmark the site to watch for more coming announcements and updates: www.USMJ.com
Contact:
USMJ
Steven Rash
info@aciconglomerated.com
+1 (800) 861-1350
Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that Alkame will achieve significant sales, the failure to meet schedule or performance requirements of the Company's contracts, the Company's liquidity position, the Company's ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
